Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MRG 003

Next Previous
Drug Profile

MRG 003

Alternative Names: MRG-003

Latest Information Update: 23 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Miracogen
  • Developer Lepu Biopharma; Miracogen
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotherapies; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Nasopharyngeal cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Nasopharyngeal cancer; Squamous cell cancer
  • Phase II Biliary cancer; Gastric cancer; Non-small cell lung cancer
  • Phase I/II Solid tumours

Most Recent Events

  • 16 May 2025 Shanghai Miracogen plans a phase III Magic-C002 trial for Nasopharyngeal cancer (Combination therapy, Recurrent, Metastatic disease, Second-line therapy or greater) in China (IV) in may 2025 (NCT06976190)
  • 06 May 2025 Groupe Oncologie Radiotherapie Tete et Cou in collaboration with Lepu Medical Technology plans a phase II IDEAL trial for Head and Neck Squamous Cell Carcinoma (Late-stage disease, Monotheray, Combination therapy) in June 2025 (IV) (NCT06959108 )
  • 31 Jul 2024 Lepu Biopharma plans a phase II trial in Squamous cell cancer (Neoadjuvant therapy, Late-stage disease, First-line therapy, Combination therapy) (IV) in August 2024 (NCT06530914)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top